| 別品名 |
Chenodiol, CDC, Chenix, Chenossil, Fluibil, Hekbilin, Ulmenide, (3α,5β,7α)-3,7-Dihydroxycholan-24-oic acid
|
| 別包装 |
あり
|
| 純度 |
>=98%
|
| 分子量 |
392.57
|
| CAS RN® |
474-25-9
|
| 化合物の概要 |
Endogenous bile acid; FXR agonist.
|
| 構造 |
C24H40O4
|
| 溶媒 |
Soluble in ethanol (20 mg/mL), methanol, acetone, or acetic acid. Practically insoluble in water, or benzene.
|
| 使用目的 |
Chenodeoxycholic acid is an endogenous bile acid synthesized by the liver; it acts as an agonist at the farnesoid X receptor (FXR). Chenodeoxycholic acid exhibits anticancer and gastrointestinal motility modulating activities. This compound treats chronic constipation and displays protective benefit against NSAID-induced gastrointestinal injury. Chenodeoxycholic acid also induces apoptosis, decreases PKC activity, and inhibits growth of ovarian cancer cells.
|
| その他 |
[融点]119℃
[外観]White to off white powder
|
| 参考文献 |
Fiorucci S, Mencarelli A, Cipriani S, et al. Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. Br J Pharmacol. 2011 Dec;164(8):1929-38. PMID: 21564085.Horowitz NS, Hua J, Powell MA, et al. Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. Gynecol Oncol. 2007 Nov;107(2):344-9. PMID: 17720233.Bazzoli F, Malavolti M, Petronelli A, et al. Treatment of constipation with chenodeoxycholic acid. J Int Med Res. 1983;11(2):120-3. PMID: 6852359.
|
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
|
※表示価格について
| 当社在庫 |
なし
|
| 納期目安 |
1週間程度
|
| 保存温度 |
常温
|
|
